<DOC>
	<DOCNO>NCT01810887</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( explores body drug ) safety darunavir , administer combination Ritonavir healthy adult Japanese male participant .</brief_summary>
	<brief_title>A Phase 4 Study Evaluate Pharmacokinetics Safety Darunavir Along With Ritonavir Healthy Male Japanese Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single oral-dose post-marketing study darunavir administer combination low-dose ritonavir healthy adult Japanese male participant . The total study duration approximately 14 day per participant . The study consist 3 part : Screening ( , 28 day study commences Day 1 ) ; Treatment ( , Day 1-5 ) ; Follow-up ( , Day 13 ) . The participant hospitalize 6 night 7 day . All eligible participant receive Darunavir oral tablet Day 3 ritonavir capsule orally twice daily Day 1-5 . Participants keep upright position 4 hour study drug administration . Both drug administer within 15 minute completion meal . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Male Participants provide sufficient explanation investigational product , drug provide clinical study prior start participation clinical study , capable provide voluntary informed consent write Male Participants Body Mass Index ( BMI ) 18.5 25.0 kilogram per square meter ( kg/m^2 ) time Screening test Nonsmokers male participant capable abstain smoking period day Screening test completion posttreatment examination Male Participants consent use medicallyapproved contraceptive method ( condom like ) period hospital admission completion posttreatment examination Male Participants show clinically significant abnormality time Screening , day prior Participants suffer history disease relate liver , kidney , circulatory system , respiratory system , digestive system , neuropsychiatric system , hematopoietic function endocrine function may inappropriate participation clinical study Participants participate another clinical study treat another investigational product within 120 day prior start initial dosing provide drug Participants give 200 milliliter ( mL ) blood within 30 day prior start initial dosing provide drug give 400 mL blood within 90 day prior start initial dosing provide drug ( blood donation ) , give total 1200 mL blood within past year Participants history hypersensitivity sulfonamide drug , drug allergy drug hypersensitivity , alcohol , pharmaceutical drug addiction , may addict Participants positive result Human Immunodeficiency Virus antigen antibody , Hepatitis C Virus antibody , Hepatitis B Surface antigen serological test syphilis</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Darunavir</keyword>
	<keyword>JNS011</keyword>
	<keyword>Ritonavir</keyword>
</DOC>